CAS 1953130-87-4

Fórmula: C18H18N4O4

InChI: InChI=1S/C18H18N4O4/c1-10(23)17-20-21-18(25-17)12-7-13(8-12)19-16(24)15-9-14(22-26-15)11-5-3-2-4-6-11/h2-6,9-10,12-13,23H,7-8H2,1H3,(H,19,24)/t10-,12?,13?/m1/s1

Chave InChI: XPEHHUISIBFLHX-QFWMXSHPSA-N

SMILES: C[C@H](C1=NN=C(O1)C2CC(C2)NC(=O)C3=CC(=NO3)C4=CC=CC=C4)O

Nesolicaftor

CAS: 1953130-87-4

Nesolicaftor

Fórmula: C₁₈H₁₈N₄O₄

Pureza: 99.5%

Peso molecular: 354.36

Ref: 54-BUP09263

Nesolicaftor

CAS: 1953130-87-4

Fórmula: C₁₈H₁₈N₄O₄

Peso molecular: 354.3599

Ref: IN-DA01V3SD

Nesolicaftor

CAS: 1953130-87-4

Nesolicaftor (PTI-428) specifically enhances cystic fibrosis transmembrane conductance regulator protein synthesis.

Fórmula: C₁₈H₁₈N₄O₄

Pureza: 99.79%

Cor e Forma: White Solid

Peso molecular: 354.3599

Ref: TM-T16681

PTI-428

CAS: 1953130-87-4

PTI-428 is a drug candidate that has been repurposed from its original use as a bronchodilator to treat cystic fibrosis (CF). It binds to the CFTR protein and stabilizes it in its open conformation, which allows for increased chloride transport. This leads to improved secretion of mucus and fluid from the lungs. PTI-428 has also been shown to be effective in treating the symptoms of cystic fibrosis by improving lung function, increasing weight gain, and reducing pulmonary exacerbations. In clinical trials, PTI-428 has been shown to improve lung function in people with CF who have the F508del mutation.

Fórmula: C₁₈H₁₈N₄O₄

Pureza: Min. 95%

Peso molecular: 354.4 g/mol

Ref: 3D-DDD13087